Research shows that people with more flow in their lives had a higher sense of well-being during the COVID-19 pandemic. Scientists are beginning to explore what happens in the brain during flow.
L’expertise universitaire, l’exigence journalistique
Articles sur FDA
Affichage de 1 à 20 de 96 articles
Knowing when and how often to use rapid tests is key to getting an accurate picture of your COVID-19 status.
The CDC’s COVID-19 vaccine provider agreement prohibits health care professionals from administering the vaccines in people for whom they are not yet authorized or approved. But this departs from longstanding norms.
Regulatory loopholes for research conducted off US soil allow for questionable trials and misleading data to slip under the FDA’s radar.
A new study suggests the market alone will not deter or punish pharmaceutical companies whose products turn out to have adverse effects after they have been approved.
When making the decision whether to vaccinate children aged five to 11 against COVID-19, regulators in Canada must rely on sound ethics as well as sound science.
Regulators are currently reviewing the safety and efficacy data of the Pfizer vaccine for five to 11 year olds before deciding whether to approve its use in this age group.
Three tobacco-flavored cartridges and a vaping device have been approved by the FDA for sale in the US. It comes after a decadelong debate over e-cigarettes.
In light of mounting research showing the serious risks of contracting COVID-19 during pregnancy, the CDC is re-upping its urgency that pregnant women get their shots.
An FDA panel has voted against recommending approval of a booster COVID-19 shot for the general population – disappointing some public health officials.
Subtly shifting the crafting and delivery of public health messaging on COVID-19 vaccines could go a long way toward persuading many of the unvaccinated to get the shot.
Making rapid antigen tests for COVID-19 cheaper and more accessible can catch the infectious cases before they spread and help everyone resume normal activities safely.
An infectious disease doctor explains the science behind COVID-19 vaccines at a level that children – and adults – of all ages can understand.
The U.S. FDA has approved the first COVID-19 vaccine. How is approval different from emergency use authorization, and what difference will it make to a vaccine that’s already in global use?
The FDA has largely lost its ability to regulate the myriad pills, powders and potions that promise to grow muscle, shed body fat and improve your focus.
While emergency use authorization gets vaccines out to the public more quickly, it doesn’t skip any steps that full approval requires.
Researchers are testing an antibody shot to protect people from Lyme disease-causing bacteria.
Ongoing tracking is meant to spot very rare risks – like the connection between the Johnson & Johnson shot and Guillain-Barré syndrome. And it relies on public reporting.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
Les contributeurs les plus fréquents
-
Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut
-
Assistant Professor of Law, Saint Louis University
-
Associate Professor of Public Policy, University of Maryland, Baltimore County
-
Professor and Dean, School of Public Health, Georgia State University
-
Professor of Law, Boston University
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Researcher, Department of Animal Science, University of California, Davis
-
Associate Professor of Operations and Decision Technologies, Kelley School of Business, Indiana University
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
-
Professor of Medicine and Executive Vice Chancellor for MassBiologics, UMass Chan Medical School
-
Instructor of Human Immunology, Emory University
-
Postdoctoral research fellow, University of Adelaide
-
Research Leader, Critical and Ethical Mental Health research group, Robinson Research Institute, University of Adelaide
-
Senior lecturer in Pharmacology, University of Adelaide
-
Infectious Disease Paediatrician and Senior Professorial Fellow, National Centre for Immunisation Research and Surveillance, University of Sydney
